Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Neoplasms 34Breast Neoplasms 34Melanoma 26Neoplasm Metastasis 24Leukemia, Myeloid, Acute 21Colorectal Neoplasms 20Prostatic Neoplasms 19Lung Neoplasms 17Multiple Myeloma 16Ovarian Neoplasms 14Recurrence 13Myelodysplastic Syndromes 13Lymphoma, Non-Hodgkin 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Hepatocellular 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Glioblastoma 10Brain Neoplasms 10Stomach Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma, Follicular 7Lymphoma 7Hodgkin Disease 7

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hepatic Impairment × 90 days × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡